Global trial aims to shield fragile kidneys from deadly heart attacks
Disease control
Ongoing
This large, late-stage trial is testing whether a low dose of the blood-thinning drug rivaroxaban can safely reduce the risk of heart attacks, strokes, and death in people with advanced or dialysis-dependent kidney disease. It will enroll 2,000 participants worldwide who have kid…
Phase: PHASE3 • Sponsor: The George Institute • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC